Abstract
In spite of optimal treatment of LDL - cholesterol, as per evidence -based guidelines, only a one third reduction in cardiovascular risk is achieved in our patients. This has led to the realization that other types of cholesterol, too, need to be treated, in order to achieve ideal cardiovascular health. The review focuses on high density lipoprotein (HDL) cholesterol as a target for treatment, its importance, relevant patents and current as well as future treatments.
Keywords: HDL cholesterol, hyperlipidemia, niacin, fibrates, statins
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Title: HDL - Cholesterol: The New Target for Treatment
Volume: 4 Issue: 2
Author(s): Sanjay Kalra, Bharti Kalra, Navneet Agrawal and Ashraf Ganie
Affiliation:
Keywords: HDL cholesterol, hyperlipidemia, niacin, fibrates, statins
Abstract: In spite of optimal treatment of LDL - cholesterol, as per evidence -based guidelines, only a one third reduction in cardiovascular risk is achieved in our patients. This has led to the realization that other types of cholesterol, too, need to be treated, in order to achieve ideal cardiovascular health. The review focuses on high density lipoprotein (HDL) cholesterol as a target for treatment, its importance, relevant patents and current as well as future treatments.
Export Options
About this article
Cite this article as:
Kalra Sanjay, Kalra Bharti, Agrawal Navneet and Ganie Ashraf, HDL - Cholesterol: The New Target for Treatment, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2010; 4 (2) . https://dx.doi.org/10.2174/187221410791196605
DOI https://dx.doi.org/10.2174/187221410791196605 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Role of Advanced Glycation End Products (AGEs) in Thrombogenic Abnormalities in Diabetes
Current Neurovascular Research Conditional Cardiac Overexpression of S100A6 Attenuates Myocyte Hypertrophy and Apoptosis Following Myocardial Infarction
Current Pharmaceutical Design The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology Nutriproteomics and Nutrigenomics: Exploring the Mechanism Behind omega-3 Polyunsaturated Fatty Acids, Homocysteine and Glucose Metabolism
Current Proteomics The Role of Transforming Growth Factor-β in Cardiac Fibrosis
Current Enzyme Inhibition Physical Activity: Do Patients Infected with HIV Practice? How Much? A Systematic Review
Current HIV Research Inotropic Therapies in Asphyxiated Neonates: The Clinical and Laboratory Facts
Current Pediatric Reviews Hyperfibrinogenemia is Significantly Associated with an Increased Risk of In-hospital Mortality in Acute Ischemic Stroke Patients
Current Neurovascular Research On the Interaction Between Human IQGAP1 and Actin
Protein & Peptide Letters Supplementation, Optimal Status, and Analytical Determination of Vitamin D: Where are we Standing in 2012?
Anti-Cancer Agents in Medicinal Chemistry Drugs that Activate Specific Nitric Oxide Sensitive Guanylyl Cyclase Isoforms Independent of Nitric Oxide Release
Current Medicinal Chemistry Chronotherapeutic Drug Delivery from Indomethacin Compression Coated Tablets for Early Morning Pain Associated Rheumatoid Arthritis
Current Drug Delivery Impact of Metabolic Surgery on Type 2 Diabetes Mellitus, Cardiovascular Risk Factors, and Mortality: A Review
Current Hypertension Reviews Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design Drug and Medical Device Interactions: Stent Thrombosis and Personalizing Clopidogrel Therapy
Current Pharmacogenomics and Personalized Medicine Thioridazine: The Good and the Bad
Recent Patents on Anti-Infective Drug Discovery Targeting Myocardial Metabolism for the Treatment of Stable Angina
Current Pharmaceutical Design Resveratrol as a Supplemental Therapeutic in Cardiovascular and Metabolic Syndromes: A Critical Review
Current Nutrition & Food Science Molecular Basis of Antiretroviral Drugs-Associated Long-Term Toxicity: How Bad can Good Drugs Be?
Current Medicinal Chemistry - Anti-Infective Agents Metabolic Programming Nowadays (or Perhaps Now and then?)
Current Nutrition & Food Science